Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart Pocock

Showing results (31-40 of 245) with videos related to

Pageof 25
Sort By:
Diabetes, Obesity & Metabolism|December 15, 2021
The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular diseaseKohei Kaku, Christoph Wanner, Stefan D Anker, et al.
Lancet (London, England)|August 31, 2018
Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trialAjay Gupta, Judith Mackay, Andrew Whitehouse, et al.
Expert Opinion on Drug Safety|April 30, 2019
Are risk minimization measures for approved drugs in Europe effective? A systematic reviewEsther Artime, Nawab Qizilbash, Macarena Garrido-Estepa, et al.
Open Heart|April 30, 2016
Prehospital and in-hospital use of healthcare resources in patients surviving acute coronary syndromes: an analysis of the EPICOR registryLieven Annemans, Nicolas Danchin, Frans Van de Werf, et al.
Heart (British Cardiac Society)|August 10, 2016
International patterns of dual antiplatelet therapy duration after acute coronary syndromesHéctor Bueno, Stuart Pocock, Nicolas Danchin, et al.
The Lancet. Healthy Longevity|September 13, 2022
Blood cholesterol and risk of dementia in more than 1·8 million people over two decades: a retrospective cohort studyMasao Iwagami, Nawab Qizilbash, John Gregson, et al.
European Heart Journal|March 12, 2013
International differences in treatment effect: do they really exist and why?Stuart Pocock, Gonzalo Calvo, Jaume Marrugat, et al.
Circulation|March 29, 2018
Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical TrialsBrian Claggett, Stuart Pocock, L J Wei, et al.
European Heart Journal. Acute Cardiovascular Care|April 4, 2018
Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR RegistryUwe Zeymer, Lieven Annemans, Nicolas Danchin, et al.
Diabetes, Obesity & Metabolism|August 24, 2017
Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic reviewKamlesh Khunti, Marilia B Gomes, Stuart Pocock, et al.
Pageof 25

Showing results (31-40 of 245) with videos related to

Sort By:
Pageof 25
Diabetes, Obesity & Metabolism|December 15, 2021
The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular diseaseKohei Kaku, Christoph Wanner, Stefan D Anker, et al.
Lancet (London, England)|August 31, 2018
Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trialAjay Gupta, Judith Mackay, Andrew Whitehouse, et al.
Expert Opinion on Drug Safety|April 30, 2019
Are risk minimization measures for approved drugs in Europe effective? A systematic reviewEsther Artime, Nawab Qizilbash, Macarena Garrido-Estepa, et al.
Open Heart|April 30, 2016
Prehospital and in-hospital use of healthcare resources in patients surviving acute coronary syndromes: an analysis of the EPICOR registryLieven Annemans, Nicolas Danchin, Frans Van de Werf, et al.
Heart (British Cardiac Society)|August 10, 2016
International patterns of dual antiplatelet therapy duration after acute coronary syndromesHéctor Bueno, Stuart Pocock, Nicolas Danchin, et al.
The Lancet. Healthy Longevity|September 13, 2022
Blood cholesterol and risk of dementia in more than 1·8 million people over two decades: a retrospective cohort studyMasao Iwagami, Nawab Qizilbash, John Gregson, et al.
European Heart Journal|March 12, 2013
International differences in treatment effect: do they really exist and why?Stuart Pocock, Gonzalo Calvo, Jaume Marrugat, et al.
Circulation|March 29, 2018
Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical TrialsBrian Claggett, Stuart Pocock, L J Wei, et al.
European Heart Journal. Acute Cardiovascular Care|April 4, 2018
Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR RegistryUwe Zeymer, Lieven Annemans, Nicolas Danchin, et al.
Diabetes, Obesity & Metabolism|August 24, 2017
Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic reviewKamlesh Khunti, Marilia B Gomes, Stuart Pocock, et al.
Pageof 25